Document 0316
 DOCN  M9490316
 TI    Secondary bacterial infections in HIV-infected patients: an alternative
       ambulatory outpatient treatment utilizing intravenous cefotaxime.
 DT    9411
 AU    Morales JO; Von Behren L; Ashford Presbyterian Community Hospital, San
       Juan, Puerto Rico; 00907.
 SO    Am J Med. 1994 Aug 15;97(2A):9-13. Unique Identifier : AIDSLINE
       MED/94337804
 AB    The purpose of this study was to determine the safety and efficacy of
       home intravenous antibiotic therapy in treating secondary bacterial
       infections in patients infected with the human immunodeficiency virus
       (HIV). This study was a subset analysis of 22 patients with HIV,
       enrolled in two centers of a multicenter, open-label, prospective study.
       When necessary, patients were stabilized as inpatients, followed by home
       therapy. Enrolled patients had diagnoses of pneumonia, skin and
       soft-tissue infections, bacteremia/septicemia, or other infections
       requiring parenteral therapy. A third-generation cephalosporin,
       cefotaxime, 1-2 g every 8 hours, was delivered intravenously using an
       ambulatory delivery system (ADS). Home therapy with cefotaxime/ADS
       produced a clinical response rate of 95% and bacteriologic response of
       88.2%. The requirement for and duration of inpatient therapy was
       markedly reduced compared with diagnosis-related group (DRG) allotments.
       In conclusion, home intravenous antibiotic therapy with cefotaxime in
       patients infected with HIV is effective and safe. It may improve quality
       of life by reducing the length of hospital stay.
 DE    Acquired Immunodeficiency Syndrome/*COMPLICATIONS  Adult  Bacterial
       Infections/COMPLICATIONS/*DRUG THERAPY  Cefotaxime/*ADMINISTRATION &
       DOSAGE/ADVERSE EFFECTS  Female  *Home Care Services  Human  *Infusion
       Pumps  Length of Stay  Male  Prospective Studies  CLINICAL TRIAL
       JOURNAL ARTICLE  MULTICENTER STUDY

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).